196 related articles for article (PubMed ID: 15300713)
1. Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy.
Baldrick P; Richardson D; Wheeler AW; Woroniecki SR
J Appl Toxicol; 2004; 24(4):261-8. PubMed ID: 15300713
[TBL] [Abstract][Full Text] [Related]
2. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy.
Baldrick P; Richardson D; Woroniecki SR; Lees B
J Appl Toxicol; 2007; 27(4):399-409. PubMed ID: 17299813
[TBL] [Abstract][Full Text] [Related]
3. A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL®) for the treatment of grass pollen allergy.
Reeve L; Baldrick P; Hewings S; Skinner M
J Appl Toxicol; 2012 Aug; 32(8):608-16. PubMed ID: 21919021
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy.
Baldrick P; Richardson D; Wheeler AW
Vaccine; 2001 Dec; 20(5-6):737-43. PubMed ID: 11738737
[TBL] [Abstract][Full Text] [Related]
5. Reproduction and juvenile animal toxicology studies in the rat with a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL(®)) for the treatment of grass pollen allergy.
Baldrick P; Hewings S; Skinner M
Reprod Toxicol; 2011 Nov; 32(3):322-8. PubMed ID: 21782016
[TBL] [Abstract][Full Text] [Related]
6. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine.
von Baehr V; Hermes A; von Baehr R; Scherf HP; Volk HD; Fischer von Weikersthal-Drachenberg KJ; Woroniecki S
J Investig Allergol Clin Immunol; 2005; 15(4):234-41. PubMed ID: 16433203
[TBL] [Abstract][Full Text] [Related]
7. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections.
Drachenberg KJ; Wheeler AW; Stuebner P; Horak F
Allergy; 2001 Jun; 56(6):498-505. PubMed ID: 11421893
[TBL] [Abstract][Full Text] [Related]
8. Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL).
Hopkins M; Lees BG; Richardson DG; Woroniecki SR; Wheeler AW
Allergol Immunopathol (Madr); 2001; 29(6):245-54. PubMed ID: 11834183
[TBL] [Abstract][Full Text] [Related]
9. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine.
Patel P; Salapatek AM
Expert Rev Vaccines; 2006 Oct; 5(5):617-29. PubMed ID: 17181436
[TBL] [Abstract][Full Text] [Related]
10. Review of L-tyrosine confirming its safe human use as an adjuvant.
Baldrick P; Richardson D; Wheeler AW
J Appl Toxicol; 2002; 22(5):333-44. PubMed ID: 12355563
[TBL] [Abstract][Full Text] [Related]
11. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination.
Linhart B; Hartl A; Jahn-Schmid B; Verdino P; Keller W; Krauth MT; Valent P; Horak F; Wiedermann U; Thalhamer J; Ebner C; Kraft D; Valenta R
J Allergy Clin Immunol; 2005 May; 115(5):1010-6. PubMed ID: 15867859
[TBL] [Abstract][Full Text] [Related]
12. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.
Wheeler AW; Marshall JS; Ulrich JT
Int Arch Allergy Immunol; 2001 Oct; 126(2):135-9. PubMed ID: 11729351
[TBL] [Abstract][Full Text] [Related]
13. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro).
McCormack PL; Wagstaff AJ
Drugs; 2006; 66(7):931-8. PubMed ID: 16740007
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents.
Drachenberg KJ; Heinzkill M; Urban E; Woroniecki SR
Allergol Immunopathol (Madr); 2003; 31(5):270-7. PubMed ID: 14572416
[TBL] [Abstract][Full Text] [Related]
15. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
16. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis.
Rosewich M; Lee D; Zielen S
Hum Vaccin Immunother; 2013 Jul; 9(7):1523-31. PubMed ID: 23584250
[TBL] [Abstract][Full Text] [Related]
17. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
18. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses.
Puggioni F; Durham SR; Francis JN
Allergy; 2005 May; 60(5):678-84. PubMed ID: 15813815
[TBL] [Abstract][Full Text] [Related]
19. Safety Evaluation of PQ Birch Allergy Immunotherapy to Support Product Development.
Baldrick P; Hutchings JW; Heath MD; Skinner MA
Regul Toxicol Pharmacol; 2019 Nov; 108():104441. PubMed ID: 31425728
[TBL] [Abstract][Full Text] [Related]
20. Date palm pollen allergoid: characterization of its chemical-physical and immunological properties.
Mistrello G; Harfi H; Roncarolo D; Kwaasi A; Zanoni D; Falagiani P; Panzani R
Int Arch Allergy Immunol; 2008; 145(3):224-30. PubMed ID: 17914274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
